Nevertheless, the results of the current experiments add strong support to the accumulating evidence suggesting that agents such as EHT that modulate PP2A activity may provide useful therapeutics for multiple neurological disorders including AD [2, 24] and other tauopathies [17, 18], as well as impairments resulting from traumatic brain injury [47–52], and Parkinson’s disease [3, 4]. The gene discussed is PTPA; the disease is tauopathy.